瑞美谷蘭 其他名稱 MRZ-8456 ATC碼
(6-Bromopyrazolo[1,5-a]pyrimidin-2-yl)[(1R )-1-methyl-3,4-dihydro-2(1H )-isoquinolinyl]methanone
CAS號 1309783-00-3 PubChem CID ChemSpider UNII CompTox Dashboard (EPA ) 化學式 C 17 H 15 Br N 4 O 摩爾質量 371.24 g·mol−1 3D模型（JSmol
C[C@@H]1c2ccccc2CCN1C(=O)c3cc4ncc(cn4n3)Br
InChI=1S/C17H15BrN4O/c1-11-14-5-3-2-4-12(14)6-7-21(11)17(23)15-8-16-19-9-13(18)10-22(16)20-15/h2-5,8-11H,6-7H2,1H3/t11-/m1/s1
Key:TUYZYSNXXSTKQX-LLVKDONJSA-N
瑞美谷蘭 （INN ：remeglurant；開發代號：MRZ-8456 ）是一種選擇性mGlu5 受體拮抗劑 的藥物。[ 1] [ 2] [ 3] 運動障礙 [ 3]
^ World Health Organization . International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 109 (PDF) . WHO Drug Information (World Health Organization ). 2013, 27 (2) [2024-03-19 ] . （原始內容存檔 (PDF) 於2022-01-20）. ^ US 7985753 ,Danysz W, Dekundy A, Hechenberger M, Henrich M, Jatzke C, Nagel J, Parsons CG, Weil T, Fotins J, Gutcaits A, Kalvinsh I, Zemribo R, Kauss V,「Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators.」,發行於4 August 2006,指定於Merz Pharmaceuticals GmbH ^ 3.0 3.1 Remeglurant . Adis Insight. Springer Nature Switzerland AG. [2024-03-19 ] . （原始內容存檔 於2024-03-19）.
